Aiming to become a specialized pharmaceutical trading company and
a top manufacturer of distinctive generic injectables
forging an entirely new type of pharmaceutical group

As the KOA SHOJI HOLDINGS Group, we continue to embrace challenges in the pharmaceutical field. KOA SHOJI, responsible for API(*) sales, KOA ISEI and KOA BIOTECH BAY engaged in pharmaceutical manufacturing and sales, along with KOA SHOJI HOLDINGS overseeing these three companies, are collectively committed to contributing to a sustainable future. We are evolving towards our mission as "The Best Partner for Generics" sharing a common vision.

Results of the Previous FY and Outlook for the Current FY

The consolidated performance of the previous FY achieved record-high sales and profits. This was driven by the contribution of profitable new product offerings in the API sales business and improvements in productivity through enhanced yield rates in the pharmaceutical manufacturing and sales business.

We anticipate continued growth in revenue and profit for the current FY. In the API sales business, the renovation of the Osaka Pharmaceutical Analysis Center is in progress and is expected to be completed within this FY. While we currently have pharmaceutical analysis centers in both Yokohama and Osaka, the completion of the renovation in Osaka will enable us to handle approximately twice the number of product offerings. As part of this plan, we will transfer some of the operations from the Yokohama center to Osaka and strengthen activities related to the development of new products in Yokohama.

In the pharmaceutical manufacturing and sales business, we are planning to establish a new warehouse within the premises of the Zao Factory during this FY. This warehouse will support the expanded production plans for Maxacalcitol and contribute to the stable supply of Lanthanum Carbonate and Cefazolin (an antibacterial agent). Cefazolin is classified as an "essential stability-assured pharmaceutical product" due to its indispensable role in medical care, making us eligible to receive "Subsidies for Supporting Stable Pharmaceutical Supply" from the Ministry of Health, Labour and Welfare.

Medium-Term Strategy and Sustainability

Looking towards the medium term, the API sales business will strengthen its internal structures and deepen collaboration with overseas suppliers to provide new value as a "pharmaceutical specialized trading company."

In the pharmaceutical manufacturing and sales business, we will proceed with facility investments while balancing with return on investment, aiming to become a top-tier manufacturer in the field of distinctive injectable medications.

We will also enhance our investment in personnel and initiatives towards environmental concerns, contributing to sustainable development.

(*) API = Active Pharmaceutical Ingredients

(Published on August 24, 2023)

KOA SHOJI HOLDINGS Co., Ltd.
President and Representative Director

Toshiyuki Shuto